ClinicalTrials.gg
RecruitingNCT07831499CEREBRAUpdated Sep 21, 2026

Cyclic vs. Constant Estradiol: Regimens' Effects on Brain Health

A Phase 4 interventional study of Cyclic Estradiol and Continuous Estradiol in Menopause, Healthy Adult and Brain, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to female participants aged 38 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
38 Years to 60 Years
Sex
Female
01

Study summary

The purpose of this study is to learn more about how estradiol patch treatment affects brain processes, health, and wellbeing.

02

Conditions studied

  • Menopause
  • Healthy Adult
  • Brain
  • Postmenopausal

Keywords

  • Estradiol
  • Estrogen
  • Menopause Hormone Therapy
  • Postmenopause
  • Brain Health
  • Neuroimaging
  • Stress
  • Extracellular Vesicles
  • Adverse Childhood Experiences
  • Cognition
  • Executive Function
03

In context

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,544 studies on the registry; 318 are open to participants now.

Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
38 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 38 to 60.
  2. Ability to give written .
  3. Fluent in written and verbal English, though may use Spanish to speak with study staff if preferred. This criterion is based on methodological necessity and feasibility, to ensure participants can accurately understand task instructions and questionnaire items which are available only in English for this pilot study.
  4. Participants must be up to date on age-appropriate cancer screening. Specifically, participants must have had a pap smear within the previous 3 years and a mammogram within the previous 2 years (American College of Obstetricians and Gynecologists, 2026; Health Resources and Services Administration, n.d.). Documentation may be requested to verify screening history.
  5. Have estradiol level below 40 pg/ml and follicle stimulating hormone (FSH) level above 25 at Van Visit Day 1. Individuals with high estradiol or low FSH levels may be retested, and eligibility determination will be at the discretion of the Principal Investigator (PI).
  6. Report final menstrual period (FMP) occurred between 12 months and 48 months at the time of screening.
  7. Right-handed.
  8. Participants are required to have at least some college education. Setting a minimum education level reduces variability due to educational disparities and supports the validity and interpretability of cognitive performance data. These tasks involve higher-order verbal learning, memory, and executive processes that can be strongly influenced by educational attainment. The investigators will re-evaluate this criterion in future larger-scale studies as resources allow.

Exclusion criteria

Exclusion Criteria:

  1. Current psychiatric diagnosis as assessed by the Mini International Neuropsychiatric Interview (MINI, Sheehan et al., 1998).
  2. Active psychiatric illness within the previous 12 months or lifetime diagnosis of a psychotic disorder.
  3. Current use of antipsychotic medications or mood stabilizers. Participants may have sporadic use of benzodiazepines during the course of the study as long as they can forgo use at least 4 days prior to study procedures.
  4. Current or history of substance use disorder within previous 12 months. However, individuals with mild disorders, disorders solely limited to cannabis or alcohol, and/or those who have achieved close to one year of remission may be eligible at the discretion of the PI.
  5. Chronic use of medication and other medications that could impact immune function and alter glucocorticoid levels.
  6. Inability to forgo use of non-steroidal anti-inflammatory medications for 4 days prior to the Baseline Visit, Van Visits, and Follow Up Visit.
  7. Any current or recent medical, psychiatric or social condition which, in the investigator's opinion, is likely to interfere with the conduct of the study, confound the interpretation of study results, or endanger the subject's well-being.
  8. Use of systemic hormone therapy (including but not limited to estradiol, progesterone, testosterone, combined hormonal , and other systemic hormonal preparations) within 3 months prior to study enrollment. Use of local vaginal estrogen therapy (e.g., vaginal cream or Estring) is permitted. For participants with a history of systemic hormone use, the study investigator may review treatment history to determine whether status can be confirmed.
  9. History of suicidal behavior within the past 2 years
  10. Undiagnosed abnormal genital bleeding.
  11. Known, suspected, or history of breast cancer.
  12. Active deep vein thrombosis, pulmonary embolism, or history of these conditions.
  13. History of cardiovascular disease
  14. Known liver dysfunction or disease.
  15. Needle phobia or history of vasovagal response to phlebotomy.
  16. History of claustrophobia or inability to tolerate a scanning environment in the past.
  17. Metal in body unsafe for magnetic resonance imaging (MRI) or other conditions that would make MRI unsafe for participants (i.e., aneurysm clip, cardiac pacemaker, etc.).
  18. Current treatment with Central nervous system (CNS) depressants (e.g., opioids, benzodiazepines).
  19. Treatment with corticosteroids within the past 30 days.
  20. Known allergy to progesterone or peanut allergy.
  21. Any history of chemotherapy as negative effects on cognitive performance have been reported for years post cessation of treatment (Guida et al., 2021; Koppelmans et al., 2012).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cyclic Estradiol

    Transdermal estradiol 100 mcg/day patch applied for 5 days every 21 days for approximately 12 weeks.

    Drug: Cyclic Estradiol

  • Experimental
    Continuous Estradiol

    Transdermal estradiol 100 mcg/day patch worn continuously and replaced every 6 days for approximately 12 weeks.

    Drug: Continuous Estradiol

Interventions

  • Participants randomized to the cyclic estradiol group apply a transdermal estradiol patch delivering 100 mcg/day for 5 days every 21 days over approximately 12 weeks. The patch is removed on the fifth day of each treatment cycle. The final patch is worn for 7 days.

    Also known as: Estradiol Patch, Transdermal Estradiol

  • Participants randomized to the continuous estradiol group apply a transdermal estradiol patch delivering 100 mcg/day continuously for approximately 12 weeks. The patch is replaced every 6 days and worn throughout the treatment period. The final patch is worn for 7 days.

    Also known as: Estradiol Patch, Transdermal Estradiol

06

What researchers measure

Primary outcomes

  1. Change in Dorsolateral Prefrontal Cortex (dlPFC) activation during working memory task in women receiving either cyclic or continuous estradiol administration.

    Description: Dorsolateral prefrontal cortex (dlPFC) activation will be measured during performance of the letter N-back task using functional magnetic resonance imaging (fMRI). Change scores will be calculated from baseline to follow-up.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  2. Change from baseline in extracellular vesicle concentration.

    Extracellular vesicle (EV) concentration will be measured from plasma samples and reported as particles per milliliter (particles/mL). Changes from baseline will be assessed following cyclic or continuous estradiol administration.

    Time frame: Baseline, Days 1-4, Days 21-24, and approximately 12 weeks after treatment initiation

  3. Change from baseline in extracellular vesicle size.

    Extracellular vesicle (EV) size will be measured from plasma samples and reported in nanometers (nm). Changes from baseline will be assessed following cyclic or continuous estradiol administration.

    Time frame: Baseline, Days 1-4, Days 21-24, and approximately 12 weeks after treatment initiation

  4. Change from baseline in extracellular vesicle zeta potential.

    Extracellular vesicle (EV) zeta potential will be measured from plasma samples and reported in millivolts (mV). Changes from baseline will be assessed following cyclic or continuous estradiol administration.

    Time frame: Baseline, Days 1-4, Days 21-24, and approximately 12 weeks after treatment initiation

  5. Change in C-reactive protein concentration.

    Serum C-reactive protein concentration measured using the Meso Scale Discovery (MSD) V-PLEX Neuroinflammation Panel.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  6. Change in interleukin concentration.

    Interleukin concentration measured using the MSD V-Plex Neuroinflammation Panel.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  7. Change in cytokine concentration.

    Cytokine concentration measured using the MSD V-Plex Neuroinflammation Panel.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  8. Change in chemokine concentration.

    Chemokine concentration measured using the MSD V-Plex Neuroinflammation Panel.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  9. Change in growth factor concentration.

    Growth factor concentration measured using the MSD V-Plex Neuroinflammation Panel.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

Secondary outcomes

  1. Change in executive function symptoms on the Brown Attention-Deficit Disorder Scale (BADDS).

    The BADDS is a validated 40-item self-report measure of executive function difficulties. Total scores range from 0 to 120, with higher scores indicating greater executive dysfunction.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  2. Change in perceived stress on the Perceived Stress Scale (PSS).

    The PSS is a 10-item self-report measure of perceived stress. Total scores range from 0 to 40, with higher scores indicating greater perceived stress.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  3. Change in depressive symptoms on the Center for Epidemiologic Studies Depression Scale (CES-D).

    The CES-D is a 20-item self-report measure of depressive symptoms. Total scores range from 0 to 60, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  4. Change in anxiety symptoms on the Generalized Anxiety Disorder-7 (GAD-7).

    The GAD-7 is a 7-item self-report measure of anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

  5. Change in hair cortisol concentration.

    Hair cortisol concentration is a biomarker of chronic hypothalamic-pituitary-adrenal axis activity. Higher concentrations indicate greater cumulative cortisol exposure over the preceding approximately three months.

    Time frame: Baseline and approximately 12 weeks after initiation of study treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 21, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Jul 15, 2028
CompletionEst.
Jul 15, 2028
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07831499
Collaborators
Pedersen Foundation
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Jul 15, 2026
Primary completion
Jul 15, 2028 (estimated)
Completion
Jul 15, 2028 (estimated)
Last update
Sep 21, 2026

Study contacts

Research Services Professional
Contact
erin.weinhold@cuanschutz.edu
‪720-281-9282‬
Neill Epperson, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion